SCHEMBL16172007

SCHEMBL16172007

CCCC(N)C(=O)N(C(C)C)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 3/20 0.39
SLC1A1 P43005 3/20 0.39
SLC1A3 P43003 2/20 0.39
GRIK1 P39086 2/20 0.39
GRIK2 Q13002 2/20 0.39
METAP1 P53582 3/20 0.36
TP53 P04637 1/20 0.36
SLC15A1 P46059 1/20 0.36
DPP4 P27487 3/20 0.36
DPP9 Q86TI2 2/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
CHRM1 P11229 1/20 0.34
AKR1A1 P14550 1/20 0.34
CHRM3 P20309 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
ADRA1A P35348 1/20 0.34
HRH1 P35367 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16171989 0.82 SLC1A3 (0.35) SLC1A2SLC1A1SLC1A3TP53SLC15A1
SCHEMBL16240651 0.79 DPP4 (0.54) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL16240652 0.79 DPP4 (0.54) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL11342489 0.77 SLC1A2 (0.42) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL8207593 0.77 SLC1A2 (0.42) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL18774973 0.76 SLC7A5 (0.54) SLC1A2SLC1A1SLC1A3DPP4DPP9
Hydrochloric Acid SCHEMBL10925209 0.76 ALDH1A1 (0.33) SLC1A2SLC1A1SLC1A3ALDH1A1
SCHEMBL9366113 0.74 BHMT (0.38) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL16240143 0.74 BHMT (0.38) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL31754346 0.74 SLC1A2 (0.39) SLC1A2SLC1A1SLC1A3GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140308304-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. 2014-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140308304-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS NPC1L1, NPC1, CETP SLC1A2 3240/4885SLC1A1 2306/4885SLC1A3 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.